BARCELONA, Spain — At the recent Heart Failure 2026 congress, a high-stakes debate unfolded regarding the role of intravenous (IV) iron supplementation in the management of heart failure (HF). While iron deficiency (ID) remains a pervasive issue in the HF population—affecting approximately half of patients with reduced ejection fraction (HFrEF)—the clinical community remains divided. The central tension lies between a growing body of evidence supporting improvements in patient-reported outcomes and the persistent failure of major randomized controlled trials (RCTs) to definitively move the needle on “hard” clinical endpoints, such as mortality and hospitalization rates.
The State of Play: A Persistent Clinical Dilemma
The prevalence of iron deficiency in patients with heart failure is well-documented, yet its optimal management remains a subject of intense scrutiny. Experts at Heart Failure 2026 convened to parse the conflicting data, questioning whether the lack of clear, positive results in large-scale trials stems from flawed trial design, improper patient selection, or a misunderstanding of how iron therapy truly impacts the heart-failure disease process.
For clinicians, the challenge is twofold: they must reconcile the "evidence-based" mandate for hard outcomes with the daily reality of patient suffering. As attendees discussed, while the scientific community debates statistical significance, patients are often left waiting for therapies that could potentially improve their day-to-day functional capacity and quality of life.
Chronology of Clinical Investigations
The history of IV iron in heart failure is characterized by a series of high-profile attempts to establish it as a cornerstone therapy.
The Early Trials and Mixed Results
The AFFIRM-AHF trial served as a notable inflection point. While it narrowly missed its primary endpoint regarding total hospitalizations and cardiovascular (CV) death, it did show a significant 26% reduction in total HF hospitalizations. Shortly thereafter, the IRONMAN trial offered further, albeit nuanced, support for iron repletion, though researchers noted that the trial’s open-label design and the disruptive influence of the COVID-19 pandemic complicated the interpretation of its primary findings.
The Recent "Failure" to Impress
The HEART-FID trial, which utilized a rigorous 99% confidence interval, failed to reach significance on its primary hierarchical composite endpoint. Despite this, a win-ratio analysis yielded a P value of 0.02 in favor of iron, suggesting that the clinical benefit might be obscured by overly conservative statistical thresholds. Similarly, FAIR-HF2—which tested IV iron specifically against heart failure hospitalizations—saw trends toward improvement that ultimately fell short of statistical significance, leaving the medical community in a state of clinical equipoise.
The Current Landscape
To date, the field is, as described by Dr. Robert Mentz, "0 for 4" in terms of trials providing an indisputably positive result for hard CV outcomes. This has led to a cautious approach by regulatory bodies and a lack of universal adoption in clinical practice, particularly in the United States, where the pathway to reimbursement for outpatient IV iron remains complex.
Supporting Data and the Meta-Analysis Argument
Despite the individual trial misses, supporters of IV iron therapy point to the "totality of evidence." A meta-analysis published in Nature Medicine in 2025 synthesized data from six major RCTs, revealing a 28% reduction in recurrent HF hospitalizations or CV death at one year, with a significant P value of 0.007.
Dr. Pieter Martens, a leading proponent of IV iron therapy, argues that looking at individual trials through a "bird’s-eye view" is a mistake. Instead, he suggests that when data is viewed in its entirety, the signal for benefit becomes clear. Martens advocates for a Class I, level of evidence B1 recommendation for patients with HFrEF and iron deficiency to reduce the composite of total heart failure hospitalizations and cardiovascular mortality.
The Problem of Diagnosis
A recurring theme during the session was the diagnostic confusion surrounding iron deficiency. Currently, ID is defined as ferritin <100 µg/L or, if transferrin saturation (TSAT) is below 20%, a ferritin between 100-300 µg/L.
Dr. Martens noted that isolated ferritin levels are often unreliable, whereas TSAT is highly predictive of outcomes. He posited that if all previous trials had strictly enrolled patients with a TSAT <20%, the results would likely have been consistently positive, potentially elevating IV iron to a "fifth pillar" of standard heart failure therapy.
Perspectives from the "Pro" and "Con" Camps
The Pro-Iron Case: Focusing on the Patient Experience
Dr. Martens emphasizes that while mortality is critical, the "function and feel" of the patient should not be disregarded. Trials like FAIR-HF and CONFIRM-HF have consistently demonstrated that IV iron improves 6-minute walk distances and overall quality of life. He described anecdotes from patients who experienced a "light switch" moment after receiving iron, suggesting that the clinical benefit is felt acutely, even if it is not always captured by traditional mortality-based endpoints.
The Con-Iron Case: The Need for Definitive Evidence
Dr. Robert Mentz, representing the skeptical view, maintained that while he is an "iron believer," there remains a lack of definitive evidence to change current clinical practice. He highlighted several areas of uncertainty, including the potential for hypophosphatemia with ferric carboxymaltose, the impact of interactions with SGLT2 inhibitors, and the possibility that the effect of iron wanes over time. For Dr. Mentz, the priority must remain on rigorous, well-designed trials—such as the ongoing ICONIC-HF study—to provide the clarity required to influence both guidelines and payer behavior.
Official Responses and Clinical Implications
The debate has had a tangible impact on global guidelines. European heart failure guidelines now recommend IV iron for symptom alleviation and quality of life improvement. In the United States, the FDA approved ferric carboxymaltose for iron repletion in 2023, and guidelines have moved toward a 2a recommendation.
However, the "trench" experience remains varied. During the session, an audience poll revealed that while most clinicians routinely screen for ID in HFrEF, the practical ability to prescribe it varies significantly. In many regions, the lack of positive cardiovascular outcome trials makes it difficult to secure the necessary logistical support for outpatient administration.
The Question of Scope
A key question raised by co-moderator Dr. Roberto Ferrari was why the focus remains so heavily on HFrEF. The panelists agreed that the lack of data in patients with heart failure with preserved ejection fraction (HFpEF) is not due to a lack of clinical relevance, but rather a lack of research. Given that ID is highly prevalent in the HFpEF population, especially in hospital settings, this represents a major "unknown" that future trials must address.
Future Directions: Where Do We Go From Here?
The consensus among the experts was that the era of ignoring iron deficiency in heart failure is over, but the era of definitive, universally accepted treatment protocols has yet to arrive.
- Standardizing Diagnosis: The medical community must move toward a more consistent definition of iron deficiency, likely prioritizing TSAT thresholds to ensure that the patients most likely to benefit are the ones being treated.
- Refining Trial Design: Future trials must account for the lessons learned from the "0 for 4" streak. This includes addressing statistical challenges and ensuring that the trial populations are homogenous enough to detect true clinical signals.
- Balancing Outcomes: The debate highlighted a permanent shift in how cardiologists view "success." While cardiovascular mortality remains the gold standard, the "function and feel" of the patient—their ability to walk, exercise, and live without the crushing fatigue of deficiency—is increasingly recognized as a vital clinical objective.
As the ICONIC-HF trial continues its recruitment, the cardiology community waits with bated breath. Whether this trial will finally provide the "win" needed to cement IV iron as a fundamental component of heart failure care remains to be seen. In the meantime, clinicians are left to navigate a middle ground, balancing the promising, albeit inconsistent, data against the profound, real-world improvements in the lives of their patients.
